Does DURVALUMAB Cause Hepatocellular carcinoma? 13 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Hepatocellular carcinoma have been filed in association with DURVALUMAB (IMFINZI). This represents 0.1% of all adverse event reports for DURVALUMAB.
13
Reports of Hepatocellular carcinoma with DURVALUMAB
0.1%
of all DURVALUMAB reports
5
Deaths
3
Hospitalizations
How Dangerous Is Hepatocellular carcinoma From DURVALUMAB?
Of the 13 reports, 5 (38.5%) resulted in death, 3 (23.1%) required hospitalization, and 1 (7.7%) were considered life-threatening.
Is Hepatocellular carcinoma Listed in the Official Label?
Yes, Hepatocellular carcinoma is listed as a known adverse reaction in the official FDA drug label for DURVALUMAB.
What Other Side Effects Does DURVALUMAB Cause?
Death (2,817)
Malignant neoplasm progression (1,330)
Pneumonitis (827)
Radiation pneumonitis (786)
Pyrexia (573)
Diarrhoea (530)
Pneumonia (453)
Dyspnoea (444)
Interstitial lung disease (430)
Off label use (395)
What Other Drugs Cause Hepatocellular carcinoma?
SORAFENIB (1,665)
RIBAVIRIN (1,046)
SOFOSBUVIR (877)
LEDIPASVIR\SOFOSBUVIR (640)
BEVACIZUMAB (532)
REGORAFENIB (470)
DACLATASVIR (419)
ATEZOLIZUMAB (342)
CABOZANTINIB S-MALATE (219)
TACROLIMUS (183)
Which DURVALUMAB Alternatives Have Lower Hepatocellular carcinoma Risk?
DURVALUMAB vs DUTASTERIDE
DURVALUMAB vs DUTASTERIDE\TAMSULOSIN
DURVALUMAB vs DUVELISIB
DURVALUMAB vs DYDROGESTERONE
DURVALUMAB vs EBASTINE